Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.80 |
| ▸ | DRD4 | P21917 | 4/20 | 0.63 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5504017 | 0.88 | SIGMAR1 (0.82) | SIGMAR1DRD4CXCR3HTR2AACHE | |
| SCHEMBL10648926 | 0.86 | SIGMAR1 (0.80) | SIGMAR1DRD4CXCR3HTR2AACHE | |
| SCHEMBL27430491 | 0.86 | SIGMAR1 (0.79) | SIGMAR1DRD4CXCR3HTR2AACHE | |
| Oxalic Acid SCHEMBL17512169 | 0.84 | SIGMAR1 (0.76) | SIGMAR1DRD4CXCR3HTR2AACHE | |
| Oxalic Acid SCHEMBL21836756 | 0.84 | SIGMAR1 (0.76) | SIGMAR1DRD4CXCR3HTR2AACHE | |
| SCHEMBL8023030 | 0.83 | SIGMAR1 (0.75) | SIGMAR1DRD4CXCR3HTR2AACHE | |
| SCHEMBL17512174 | 0.82 | DRD4 (0.76) | SIGMAR1DRD4HTR2A | |
| SCHEMBL31486979 | 0.81 | SIGMAR1 (0.71) | SIGMAR1DRD4 | |
| SCHEMBL17512172 | 0.80 | SIGMAR1 (0.70) | SIGMAR1DRD4CXCR3HTR2A | |
| SCHEMBL10514979 | 0.80 | SIGMAR1 (0.79) | SIGMAR1DRD4CXCR3HTR2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023133135-A2 | SMALL MOLECULE ADRENORECEPTOR ANTAGONISTS AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2023-07-13 | — | — | WO | disclosed |